Search results for "MESH: Comorbidity"

showing 4 items of 4 documents

ST-segment elevation myocardial infarction: Management and association with prognosis during the COVID-19 pandemic in France.

2021

Systems of care have been challenged to control progression of the COVID-19 pandemic. Whether this has been associated with delayed reperfusion and worse outcomes in French patients with ST-segment elevation myocardial infarction (STEMI) is unknown.Aim: To compare the rate of STEMI admissions, treatment delays, and outcomes between the first peak of the COVID-19 pandemic in France and the equivalent period in 2019.Methods: In this nationwide French survey, data from consecutive STEMI patients from 65 centres referred for urgent revascularization between 1 March and 31 May 2020, and between 1 March and 31 May 2019, were analysed. The primary outcome was a composite of in-hospital death or no…

MaleMESH: Hyperlipidemiasmedicine.medical_treatmentMESH: ComorbidityComorbidity030204 cardiovascular system & hematologyMESH: Health Care SurveysMESH: HypertensionMESH: Procedures and Techniques Utilization0302 clinical medicinePatient AdmissionInterquartile rangeMESH: Risk FactorsRisk FactorsST segmentMESH: COVID-19030212 general & internal medicineMyocardial infarctionHospital MortalityMESH: Treatment Outcomeeducation.field_of_studyMESH: Middle AgedCardiogenic shockSmokingMESH: Patient Acceptance of Health CareGeneral MedicineMESH: Heart Rupture Post-InfarctionMiddle AgedPrognosis[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemTreatment OutcomeHypertensionCardiologyFemaleStentsFranceCardiology and Cardiovascular MedicineSCA ST+MESH: Percutaneous Coronary Interventionmedicine.medical_specialtyMESH: PandemicsMESH: SmokingMESH: Diabetes MellitusPopulationComplications mécaniquesHyperlipidemiasRevascularizationMESH: PrognosisTime-to-TreatmentSTEMI03 medical and health sciencesPercutaneous Coronary Intervention[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemInternal medicineLockdownmedicineDiabetes MellitusHumansMESH: SARS-CoV-2MESH: Time-to-TreatmentMESH: Hospital MortalityMESH: ST Elevation Myocardial InfarctioneducationPandemicsHeart Rupture Post-InfarctionMESH: Humansbusiness.industryMESH: Patient AdmissionSARS-CoV-2Percutaneous coronary interventionCOVID-19Patient Acceptance of Health Caremedicine.diseaseComorbidityMESH: MaleMESH: FranceMESH: Stents[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieHealth Care SurveysST Elevation Myocardial Infarction[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieMechanical complicationsbusinessMESH: FemaleProcedures and Techniques UtilizationConfinementArchives of cardiovascular diseases
researchProduct

Incremental predictive value of mean platelet volume/platelet count ratio in in-hospital stroke after acute myocardial infarction.

2017

IF 2.558; International audience; Stroke is a serious complication after acute myocardial infarction (AMI) and is associated with an increased risk of death. Though the pathophysiological mechanisms are not exactly known, increased inflammation and platelet reactivity could play an important role in the occurrence of stroke during AMI. We aimed to investigate the relationship between both mean platelet volume (MPV), a parameter of platelet function, and C-reactive protein (CRP) and the occurrence of in-hospital ischemic stroke (IHS) after AMI. Data were obtained from a French regional survey for AMI that included 5976 patients admitted to an intensive care unit (ICU) between 2001 and 2010. …

MaleTime FactorsMESH : StrokeMyocardial InfarctionMESH : AgedMESH: ComorbidityComorbidityMESH: Hospitalization030204 cardiovascular system & hematologyMESH : Platelet Countlaw.inventionMESH: Proportional Hazards Models0302 clinical medicineMESH: Aged 80 and overRisk FactorslawMESH: Risk FactorsOdds Ratio[ SDV.MHEP.HEM ] Life Sciences [q-bio]/Human health and pathology/HematologyMESH : FemaleMyocardial infarctionMESH : BiomarkersStrokeMESH: Blood PlateletsAged 80 and overMESH: AgedEjection fractionMESH: Middle AgedMESH : PrognosisbiologyMESH : Mean Platelet Volume[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/HematologyHematologyGeneral MedicineMiddle AgedPrognosisIntensive care unitstrokeMESH : Risk Factors3. Good healthHospitalizationMESH: Myocardial Infarctionrisk factorplateletsMESH : ComorbidityCardiologyMESH : HospitalizationFemaleMean Platelet VolumeMESH : Time FactorsBlood Plateletsmedicine.medical_specialtyMESH : Male[SDV.BC]Life Sciences [q-bio]/Cellular BiologyAcute myocardial infarctionMESH: PrognosisMESH: StrokeC-reactive protein03 medical and health sciencesInternal medicinemedicineHumansMESH : Middle AgedMESH: Platelet Countcardiovascular diseasesRisk factorMean platelet volumeMESH : Aged 80 and overSurvival analysisAgedProportional Hazards ModelsMESH: HumansPlatelet Countbusiness.industry[ SDV.BC ] Life Sciences [q-bio]/Cellular BiologyC-reactive proteinMESH: Time FactorsMESH : HumansMESH : Blood Plateletsmedicine.diseaseMESH : Proportional Hazards ModelsMESH: Odds RatioMESH: MaleMESH: Mean Platelet Volumebiology.proteinMESH: BiomarkersMESH : Odds RatioMESH : Myocardial InfarctionbusinessMESH: FemaleBiomarkers030217 neurology & neurosurgery
researchProduct

Factors related to the relative survival of patients with diffuse large B-cell lymphoma in a population-based study in France: does socio-economic st…

2017

IF 7.702; International audience; The survival of patients with diffuse large B-cell lymphoma has increased during the last decade as a result of addition of anti-CD20 to anthracycline-based chemotherapy. Although the trend is encouraging, there are persistent differences in survival within and between the USA and European countries suggesting that non-biological factors play a role. Our aim was to investigate the influence of such factors on relative survival of patients with diffuse large B-cell lymphoma. We conducted a retrospective, multicenter, registry-based study in France on 1165 incident cases of diffuse large B-cell lymphoma between 2002 and 2008. Relative survival analyses were p…

[SDV.MHEP.HEM] Life Sciences [q-bio]/Human health and pathology/HematologyMale0301 basic medicinePediatricsMultivariate analysisMESH: RegistriesMESH : AgedMESH: ComorbidityComorbidityMESH : Lymphoma Large B-Cell DiffuseMESH: Aged 80 and over0302 clinical medicineInternational Prognostic IndexMESH : ChildMESH: ChildMESH : Population Surveillance[ SDV.MHEP.HEM ] Life Sciences [q-bio]/Human health and pathology/HematologyMESH : FemaleRegistriesYoung adultChildAged 80 and overMESH: AgedMESH: Middle AgedMESH : PrognosisRelative survivalMESH: Patient Outcome Assessment[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/HematologyArticlesHematologyMiddle AgedMESH : AdultPrognosisMESH : Patient Outcome Assessment3. Good healthMESH: Young AdultPopulation SurveillanceMESH: Survival Analysis030220 oncology & carcinogenesisMESH : ComorbidityMarital statusFemaleFranceLymphoma Large B-Cell DiffuseNon-Hodgkin LeukemiaAdultmedicine.medical_specialtyAdolescentMESH : MaleMESH: Factor Analysis StatisticalMESH : Young AdultMESH : Factor Analysis StatisticalMESH: PrognosisMESH: Population SurveillanceMESH: Social ClassYoung Adult03 medical and health sciencesMESH : AdolescentInternal medicineMESH : Social ClassmedicineHumansMESH : Middle AgedMESH : Aged 80 and overMESH : FranceSurvival analysisAgedMESH: AdolescentMESH: Humansbusiness.industryMESH : HumansMESH: Adultmedicine.diseaseSurvival AnalysisComorbidityMESH: MalePatient Outcome AssessmentMESH: France030104 developmental biologySocial ClassMESH: Lymphoma Large B-Cell DiffuseMESH : Survival AnalysisFactor Analysis StatisticalbusinessMESH: FemaleDiffuse large B-cell lymphomaMESH : RegistriesHaematologica
researchProduct

Is COVID‐19 infection more severe in kidney transplant recipients?

2021

International audience; There are no studies which have compared the risk of severe Covid-19 and related mortality between transplant recipients and non-transplant patients. We enrolled two groups of patients hospitalized for Covid-19, i.e., kidney transplant recipients from the French Registry of Solid Organ Transplant (n=306) and a single-center cohort of non-transplant patients (n=795). An analysis was performed among subgroups matched for age and risk factors for severe Covid-19 or mortality. Severe Covid-19 was defined as admission (or transfer) to an intensive care unit, need for mechanical ventilation, or death.Transplant recipients were younger and had more comorbidities compared to…

medicine.medical_treatment[SDV]Life Sciences [q-bio]MESH: Registries*AucunMESH: Comorbidity030230 surgerylaw.inventionchemistry.chemical_compound0302 clinical medicinelawcardiovascular diseaseMESH: Risk Factors[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesclinical research / practiceImmunology and AllergyCumulative incidencePharmacology (medical)kidney transplantation / nephrologyMESH: IncidenceMESH: AgedUnivariate analysisMESH: France / epidemiologyMESH: Middle AgedMESH: Transplant Recipients / statistics & numerical data*Acute kidney injuryIntensive care unit3. Good healthMESH: COVID-19 / epidemiologyCohort[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseasesglomerular filtration rate (GFR)kidney failure / injurymedicine.medical_specialtyinfection and infectious agents - viralinfectious diseaseBrief CommunicationMESH: Graft Rejection / prevention & control03 medical and health sciencesInternal medicineDiabetes mellitusMESH: Severity of Illness IndexMESH: COVID-19 / diagnosis*medicineHumansMESH: SARS-CoV-2Mechanical ventilationCreatinineTransplantationMESH: Humansbusiness.industrySARS-CoV-2MESH: Graft Rejection / epidemiology*COVID-19MESH: Retrospective Studiesmedicine.diseaseKidney TransplantationTransplant RecipientsMESH: Maleimmunosuppressive regimensMESH: Immunosuppressive Agents / therapeutic useMESH: Pandemics*MESH: Propensity Score*chemistryReinfectionMESH: Immunosuppression / methodsMESH: Intensive Care UnitsbusinessMESH: FemaleMESH: Kidney Transplantation*
researchProduct